Alkermes plc (ALKS)
USD 30.05
(-5.1%)
USD 30.05
(-5.1%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.13 Billion USD | 8.77% |
| 2022 | 1.96 Billion USD | -2.99% |
| 2021 | 2.02 Billion USD | 3.83% |
| 2020 | 1.94 Billion USD | 7.99% |
| 2019 | 1.8 Billion USD | -1.07% |
| 2018 | 1.82 Billion USD | 1.55% |
| 2017 | 1.79 Billion USD | 4.1% |
| 2016 | 1.72 Billion USD | -6.97% |
| 2015 | 1.85 Billion USD | -3.41% |
| 2014 | 1.92 Billion USD | 30.67% |
| 2013 | 1.47 Billion USD | 2.44% |
| 2012 | 1.43 Billion USD | 217.21% |
| 2011 | 452.44 Million USD | -12.25% |
| 2010 | 515.6 Million USD | -8.98% |
| 2009 | 566.48 Million USD | -13.69% |
| 2008 | 656.31 Million USD | 15.42% |
| 2007 | 568.62 Million USD | 19.17% |
| 2006 | 477.16 Million USD | 40.81% |
| 2005 | 338.87 Million USD | 25.5% |
| 2004 | 270.02 Million USD | 5.6% |
| 2003 | 255.69 Million USD | -27.02% |
| 2002 | 350.35 Million USD | -10.46% |
| 2001 | 391.29 Million USD | -5.47% |
| 2000 | 413.96 Million USD | 93.94% |
| 1999 | 213.45 Million USD | -3.09% |
| 1998 | 220.25 Million USD | 110.38% |
| 1997 | 104.69 Million USD | 128.6% |
| 1996 | 45.8 Million USD | 24.8% |
| 1995 | 36.7 Million USD | -20.73% |
| 1994 | 46.3 Million USD | -14.26% |
| 1993 | 54 Million USD | -3.05% |
| 1992 | 55.7 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 2.12 Billion USD | -0.58% |
| 2024 Q3 | 2.15 Billion USD | -2.34% |
| 2024 Q2 | 2.2 Billion USD | 3.91% |
| 2023 Q3 | 2.27 Billion USD | 4.21% |
| 2023 Q2 | 2.18 Billion USD | 13.75% |
| 2023 Q4 | 2.13 Billion USD | -6.27% |
| 2023 Q1 | 1.92 Billion USD | -2.1% |
| 2023 FY | 2.13 Billion USD | 8.77% |
| 2022 Q1 | 1.97 Billion USD | -2.3% |
| 2022 Q2 | 1.95 Billion USD | -1.03% |
| 2022 Q3 | 1.94 Billion USD | -0.79% |
| 2022 Q4 | 1.96 Billion USD | 1.14% |
| 2022 FY | 1.96 Billion USD | -2.99% |
| 2021 FY | 2.02 Billion USD | 3.83% |
| 2021 Q3 | 1.99 Billion USD | 2.99% |
| 2021 Q2 | 1.93 Billion USD | 3.16% |
| 2021 Q4 | 2.02 Billion USD | 1.46% |
| 2021 Q1 | 1.87 Billion USD | -3.67% |
| 2020 Q2 | 1.8 Billion USD | -1.29% |
| 2020 Q4 | 1.94 Billion USD | 3.88% |
| 2020 FY | 1.94 Billion USD | 7.99% |
| 2020 Q1 | 1.82 Billion USD | 1.14% |
| 2020 Q3 | 1.87 Billion USD | 4.13% |
| 2019 Q1 | 1.75 Billion USD | -3.75% |
| 2019 Q4 | 1.8 Billion USD | 2.7% |
| 2019 Q3 | 1.75 Billion USD | 0.36% |
| 2019 Q2 | 1.75 Billion USD | -0.27% |
| 2019 FY | 1.8 Billion USD | -1.07% |
| 2018 Q1 | 1.73 Billion USD | -3.38% |
| 2018 Q4 | 1.82 Billion USD | 3.65% |
| 2018 Q3 | 1.76 Billion USD | 0.53% |
| 2018 Q2 | 1.75 Billion USD | 0.86% |
| 2018 FY | 1.82 Billion USD | 1.55% |
| 2017 FY | 1.79 Billion USD | 4.1% |
| 2017 Q4 | 1.79 Billion USD | 2.8% |
| 2017 Q3 | 1.74 Billion USD | 0.98% |
| 2017 Q2 | 1.73 Billion USD | 0.09% |
| 2017 Q1 | 1.72 Billion USD | 0.2% |
| 2016 FY | 1.72 Billion USD | -6.97% |
| 2016 Q4 | 1.72 Billion USD | 1.12% |
| 2016 Q1 | 1.79 Billion USD | -3.28% |
| 2016 Q2 | 1.78 Billion USD | -0.53% |
| 2016 Q3 | 1.7 Billion USD | -4.36% |
| 2015 Q3 | 1.88 Billion USD | -1.76% |
| 2015 Q2 | 1.91 Billion USD | -0.52% |
| 2015 Q4 | 1.85 Billion USD | -1.34% |
| 2015 FY | 1.85 Billion USD | -3.41% |
| 2015 Q1 | 1.92 Billion USD | 0.18% |
| 2014 Q3 | 1.83 Billion USD | -1.06% |
| 2014 Q2 | 1.85 Billion USD | 1.2% |
| 2014 Q1 | 1.83 Billion USD | 16.35% |
| 2014 FY | 1.92 Billion USD | 30.67% |
| 2014 Q4 | 1.92 Billion USD | 4.54% |
| 2013 Q1 | 1.47 Billion USD | 4.15% |
| 2013 Q4 | 1.57 Billion USD | 4.31% |
| 2013 Q3 | 1.51 Billion USD | 2.34% |
| 2013 Q2 | 1.47 Billion USD | 0.51% |
| 2013 FY | 1.47 Billion USD | 2.44% |
| 2012 FY | 1.43 Billion USD | 217.21% |
| 2012 Q1 | 1.43 Billion USD | -4.69% |
| 2012 Q2 | 1.44 Billion USD | 0.73% |
| 2012 Q3 | 1.37 Billion USD | -5.2% |
| 2012 Q4 | 1.41 Billion USD | 3.01% |
| 2011 Q4 | 1.5 Billion USD | 0.11% |
| 2011 FY | 452.44 Million USD | -12.25% |
| 2011 Q1 | 452.44 Million USD | 1.12% |
| 2011 Q2 | 451.23 Million USD | -0.27% |
| 2011 Q3 | 1.5 Billion USD | 233.33% |
| 2010 Q1 | 515.6 Million USD | -0.83% |
| 2010 FY | 515.6 Million USD | -8.98% |
| 2010 Q4 | 447.43 Million USD | -0.38% |
| 2010 Q3 | 449.13 Million USD | -8.66% |
| 2010 Q2 | 491.74 Million USD | -4.63% |
| 2009 Q1 | 566.48 Million USD | -5.06% |
| 2009 Q2 | 535.21 Million USD | -5.52% |
| 2009 Q3 | 527.27 Million USD | -1.48% |
| 2009 FY | 566.48 Million USD | -13.69% |
| 2009 Q4 | 519.9 Million USD | -1.4% |
| 2008 Q1 | 656.31 Million USD | -10.15% |
| 2008 Q3 | 605.01 Million USD | -6.75% |
| 2008 Q4 | 596.66 Million USD | -1.38% |
| 2008 FY | 656.31 Million USD | 15.42% |
| 2008 Q2 | 648.83 Million USD | -1.14% |
| 2007 Q3 | 572.88 Million USD | 1.53% |
| 2007 FY | 568.62 Million USD | 19.17% |
| 2007 Q1 | 568.62 Million USD | 0.93% |
| 2007 Q4 | 730.48 Million USD | 27.51% |
| 2007 Q2 | 564.25 Million USD | -0.77% |
| 2006 Q3 | 544.1 Million USD | -2.45% |
| 2006 Q1 | 477.16 Million USD | -1.12% |
| 2006 Q2 | 557.75 Million USD | 16.89% |
| 2006 FY | 477.16 Million USD | 40.81% |
| 2006 Q4 | 563.37 Million USD | 3.54% |
| 2005 FY | 338.87 Million USD | 25.5% |
| 2005 Q2 | 487.44 Million USD | 43.84% |
| 2005 Q1 | 338.87 Million USD | 67.92% |
| 2005 Q3 | 488.54 Million USD | 0.22% |
| 2005 Q4 | 482.55 Million USD | -1.23% |
| 2004 Q1 | 270.02 Million USD | -8.98% |
| 2004 Q2 | 235.25 Million USD | -12.88% |
| 2004 Q3 | 214.27 Million USD | -8.92% |
| 2004 Q4 | 201.81 Million USD | -5.82% |
| 2004 FY | 270.02 Million USD | 5.6% |
| 2003 Q2 | 226.31 Million USD | -11.49% |
| 2003 Q4 | 296.66 Million USD | -5.46% |
| 2003 Q3 | 313.81 Million USD | 38.66% |
| 2003 Q1 | 255.69 Million USD | -12.17% |
| 2003 FY | 255.69 Million USD | -27.02% |
| 2002 Q4 | 291.13 Million USD | 29.9% |
| 2002 Q3 | 224.12 Million USD | -24.69% |
| 2002 Q2 | 297.6 Million USD | -15.06% |
| 2002 Q1 | 350.35 Million USD | -9.31% |
| 2002 FY | 350.35 Million USD | -10.46% |
| 2001 FY | 391.29 Million USD | -5.47% |
| 2001 Q1 | 391.29 Million USD | -3.05% |
| 2001 Q4 | 386.32 Million USD | 4.62% |
| 2001 Q3 | 369.27 Million USD | -3.97% |
| 2001 Q2 | 384.55 Million USD | -1.72% |
| 2000 Q4 | 403.62 Million USD | -3.4% |
| 2000 FY | 413.96 Million USD | 93.94% |
| 2000 Q3 | 417.81 Million USD | -2.1% |
| 2000 Q1 | 413.96 Million USD | 94.31% |
| 2000 Q2 | 426.79 Million USD | 3.1% |
| 1999 FY | 213.45 Million USD | -3.09% |
| 1999 Q2 | 233.36 Million USD | 9.33% |
| 1999 Q3 | 223.3 Million USD | -4.31% |
| 1999 Q1 | 213.45 Million USD | -3.21% |
| 1999 Q4 | 213.04 Million USD | -4.59% |
| 1998 FY | 220.25 Million USD | 110.38% |
| 1998 Q1 | 220.25 Million USD | 110.99% |
| 1998 Q3 | 221.49 Million USD | 4.21% |
| 1998 Q4 | 220.52 Million USD | -0.44% |
| 1998 Q2 | 212.53 Million USD | -3.5% |
| 1997 Q4 | 104.39 Million USD | -2.83% |
| 1997 FY | 104.69 Million USD | 128.6% |
| 1997 Q1 | 104.69 Million USD | 81.73% |
| 1997 Q2 | 101.18 Million USD | -3.36% |
| 1997 Q3 | 107.43 Million USD | 6.18% |
| 1996 FY | 45.8 Million USD | 24.8% |
| 1996 Q2 | 62.12 Million USD | 35.64% |
| 1996 Q3 | 62.18 Million USD | 0.1% |
| 1996 Q1 | 45.8 Million USD | -9.84% |
| 1996 Q4 | 57.61 Million USD | -7.36% |
| 1995 Q1 | 36.7 Million USD | 0.27% |
| 1995 FY | 36.7 Million USD | -20.73% |
| 1995 Q3 | 47.1 Million USD | 46.27% |
| 1995 Q4 | 50.8 Million USD | 7.86% |
| 1995 Q2 | 32.2 Million USD | -12.26% |
| 1994 Q1 | 46.3 Million USD | -4.93% |
| 1994 Q2 | 40.2 Million USD | -13.17% |
| 1994 Q3 | 37.9 Million USD | -5.72% |
| 1994 Q4 | 36.6 Million USD | -3.43% |
| 1994 FY | 46.3 Million USD | -14.26% |
| 1993 Q2 | 48.2 Million USD | -10.74% |
| 1993 Q4 | 48.7 Million USD | 10.43% |
| 1993 Q1 | 54 Million USD | 0.75% |
| 1993 Q3 | 44.1 Million USD | -8.51% |
| 1993 FY | 54 Million USD | -3.05% |
| 1992 Q3 | 53.5 Million USD | -5.31% |
| 1992 FY | 55.7 Million USD | 0.0% |
| 1992 Q2 | 56.5 Million USD | 1.44% |
| 1992 Q1 | 55.7 Million USD | 0.0% |
| 1992 Q4 | 53.6 Million USD | 0.19% |
| 1991 Q3 | 22.1 Million USD | 513.89% |
| 1991 Q2 | 3.6 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | -43.554% |
| Agenus Inc. | 313.91 Million USD | -580.514% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 44.222% |
| Aptorum Group Limited | 20.64 Million USD | -10249.872% |
| Ardelyx, Inc. | 297.57 Million USD | -617.868% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -179.043% |
| Bicycle Therapeutics plc | 595.34 Million USD | -258.822% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -2798.46% |
| ChromaDex Corporation | 54.96 Million USD | -3786.586% |
| Chimerix, Inc. | 212.77 Million USD | -903.987% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -7455.862% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -384.439% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 4.187% |
| Precision BioSciences, Inc. | 159.78 Million USD | -1236.969% |
| Dyadic International, Inc. | 8.21 Million USD | -25890.53% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -6630.381% |
| Fortress Biotech, Inc. | 167.52 Million USD | -1175.159% |
| Lantern Pharma Inc. | 43.64 Million USD | -4794.249% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -1224.075% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -14625.822% |
| Incyte Corporation | 6.78 Billion USD | 68.502% |
| IO Biotech, Inc. | 150.71 Million USD | -1317.364% |
| Jaguar Health, Inc. | 50.76 Million USD | -4108.228% |
| Novavax, Inc. | 1.85 Billion USD | -15.139% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -461.562% |
| Opthea Limited | 188.79 Million USD | -1031.527% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | -156.43% |
| ContextLogic Inc. | 423 Million USD | -405.017% |
| MiMedx Group, Inc. | 239.04 Million USD | -793.641% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -1129.651% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -41221.984% |
| NextCure, Inc. | 129.41 Million USD | -1550.638% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -3859.782% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -5716.175% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -6513.489% |
| Vaxcyte, Inc. | 1.4 Billion USD | -51.729% |
| PDS Biotechnology Corporation | 59.39 Million USD | -3496.936% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -233.5% |
| Pharming Group N.V. | 462.85 Million USD | -361.533% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -5422.81% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -239.863% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -11188.627% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -11188.627% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -1192.175% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -4617.078% |
| Acelyrin, Inc. | 742.69 Million USD | -187.633% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -32333.243% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -33262.846% |
| Summit Therapeutics Inc. | 202.94 Million USD | -952.591% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -2772.271% |
| Senti Biosciences, Inc. | 119.48 Million USD | -1687.874% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -835.537% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -1170.246% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -25752.874% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -44649.2% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -355.298% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -1627.595% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -676.952% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -351.786% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -21040.257% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -895.88% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -188585.776% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -416.193% |
| Immix Biopharma, Inc. | 19.92 Million USD | -10621.234% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -477.319% |
| MEI Pharma, Inc. | 41.37 Million USD | -5063.077% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -6492.06% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -526.83% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -1722.327% |
| Fortress Biotech, Inc. | 167.52 Million USD | -1175.159% |
| Precigen, Inc. | 151.04 Million USD | -1314.314% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -6179.684% |
| AlloVir, Inc. | 190.79 Million USD | -1019.637% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -467.464% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -321.997% |
| ImmuCell Corporation | 43.8 Million USD | -4776.319% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -228.996% |
| Onconetix, Inc. | 88.82 Million USD | -2305.076% |
| PureTech Health plc | 693.97 Million USD | -207.825% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -2086.849% |
| Elevation Oncology, Inc. | 89.09 Million USD | -2297.799% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -34344.099% |
| Seer, Inc. | 436.26 Million USD | -389.657% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -2518.017% |
| Innoviva, Inc. | 1.24 Billion USD | -71.79% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -1513.181% |
| ESSA Pharma Inc. | 149.12 Million USD | -1332.533% |
| GlycoMimetics, Inc. | 45.31 Million USD | -4614.01% |
| GT Biopharma, Inc. | 14.1 Million USD | -15040.853% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -593.82% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -783.821% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -352.679% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -4113.707% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -2143.649% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -338130.46% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -277.197% |
| Aptose Biosciences Inc. | 12.92 Million USD | -16430.979% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -9559.924% |
| Soligenix, Inc. | 9.79 Million USD | -21704.143% |
| Century Therapeutics, Inc. | 360.69 Million USD | -492.258% |
| Kura Oncology, Inc. | 448.93 Million USD | -375.842% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -684.946% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -12251.68% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -1826.064% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -941.293% |
| Autolus Therapeutics plc | 375.38 Million USD | -469.081% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -748.934% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -501.441% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -4247.926% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -223.115% |
| GRI Bio, Inc. | 2.95 Million USD | -72167.355% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -20043.116% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -1152.806% |
| IGM Biosciences, Inc. | 423.41 Million USD | -404.527% |
| INmune Bio, Inc. | 57 Million USD | -3647.694% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -860.074% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -2444.902% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -8079.479% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -30935.34% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -2739.74% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -1350.667% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -1190.738% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -239.296% |
| Verastem, Inc. | 149.71 Million USD | -1326.831% |
| Abeona Therapeutics Inc. | 64 Million USD | -3237.744% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -317.106% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -1283.054% |
| Histogen Inc. | 19.07 Million USD | -11100.246% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -9331.376% |
| Surrozen, Inc. | 46.08 Million USD | -4535.901% |
| Organovo Holdings, Inc. | 6.34 Million USD | -33546.606% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -49480.214% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -1383.212% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -18000.517% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -2738.156% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -24975.247% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -488.541% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -11705.992% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -397.488% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -16838.395% |
| Apollomics, Inc. | 55.38 Million USD | -3756.903% |
| Amarin Corporation plc | 831.68 Million USD | -156.855% |
| Mesoblast Limited | 669.15 Million USD | -219.243% |
| Turnstone Biologics Corp. | 112.81 Million USD | -1793.563% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -271.027% |
| Synaptogenix, Inc. | 31.11 Million USD | -6765.867% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -17433.019% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -289.778% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -36278.203% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -28983.414% |
| Exelixis, Inc. | 2.94 Billion USD | 27.398% |
| Better Therapeutics, Inc. | 22.94 Million USD | -9211.001% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -486.007% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -170.843% |
| NLS Pharmaceutics AG | 1.84 Million USD | -115581.554% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -26674.295% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -14437.074% |
| Gritstone bio, Inc. | 177.76 Million USD | -1101.685% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -2139.697% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -11859.415% |
| Avid Bioservices, Inc. | 336.55 Million USD | -534.728% |
| Insmed Incorporated | 1.32 Billion USD | -60.638% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -22086.814% |
| MediWound Ltd. | 66.45 Million USD | -3114.347% |
| OmniAb, Inc. | 401.98 Million USD | -431.419% |
| Alector, Inc. | 621.82 Million USD | -243.54% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -495.712% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -39621.514% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -3668.121% |
| Zai Lab Limited | 1.03 Billion USD | -106.14% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -346.485% |
| Aura Biosciences, Inc. | 255.07 Million USD | -737.488% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -184.819% |
| Immunic, Inc. | 54.29 Million USD | -3834.185% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -702.416% |
| Veracyte, Inc. | 1.13 Billion USD | -87.747% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -17968.7% |
| FibroGen, Inc. | 423.52 Million USD | -404.386% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -60709.081% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -45000.299% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -39244.906% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 81.25% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -24161.476% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -312.833% |
| TG Therapeutics, Inc. | 329.58 Million USD | -548.151% |
| Galecto, Inc. | 38.22 Million USD | -5488.257% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -7349.515% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 50.973% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -807.471% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -8499.239% |
| XBiotech Inc. | 227.24 Million USD | -840.061% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -2139.697% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -1398.053% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -647.151% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -1570.634% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -459.222% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | -43.273% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -485.52% |
| Vaxxinity, Inc. | 44.35 Million USD | -4716.412% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -313.228% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -11379.311% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -600.286% |
| NexImmune, Inc. | 8.59 Million USD | -24757.292% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -19836.399% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -12372.553% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 93.542% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -9543.855% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -544486.695% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -1132.467% |
| Ainos, Inc. | 31.84 Million USD | -6608.863% |
| Pluri Inc. | 39.52 Million USD | -5304.465% |
| Prothena Corporation plc | 696.38 Million USD | -206.76% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -655.875% |
| Celularity Inc. | 143.88 Million USD | -1384.633% |
| Rallybio Corporation | 115.62 Million USD | -1747.624% |
| Cue Biopharma, Inc. | 61.53 Million USD | -3371.84% |
| MeiraGTx Holdings plc | 458.16 Million USD | -366.253% |
| Omeros Corporation | 378.26 Million USD | -464.736% |
| Humacyte, Inc. | 128.22 Million USD | -1566.022% |
| Immunocore Holdings plc | 597 Million USD | -257.826% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -6733.945% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -3017.209% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -103.595% |
| CalciMedica, Inc. | 12.18 Million USD | -17431.58% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -742.193% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -1149.926% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -586.811% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -277.893% |
| Pulmatrix, Inc. | 33.95 Million USD | -6190.78% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -7769.384% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -1416.579% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -64.201% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -1540.863% |
| Cytokinetics, Incorporated | 824.31 Million USD | -159.151% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -10013.256% |
| Nutriband Inc. | 7.51 Million USD | -28317.976% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -2605.655% |
| Vor Biopharma Inc. | 209.82 Million USD | -918.083% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 70.423% |
| Evogene Ltd. | 51.1 Million USD | -4080.394% |
| ProKidney Corp. | 420.55 Million USD | -407.957% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -3795.871% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -22338.662% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -290.978% |
| CorMedix Inc. | 82.05 Million USD | -2503.247% |
| BioLineRx Ltd. | 63.92 Million USD | -3241.765% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -430.65% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -7475.259% |
| Atai Life Sciences N.V. | 293.47 Million USD | -627.899% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -1209.526% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -1576.547% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -280.093% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -2108.69% |
| MediciNova, Inc. | 66.26 Million USD | -3123.516% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -2328.961% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -47771.992% |
| GeoVax Labs, Inc. | 9.28 Million USD | -22911.662% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -263.157% |
| Biomea Fusion, Inc. | 199.92 Million USD | -968.502% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | -12.245% |
| Mereo BioPharma Group plc | 66.49 Million USD | -3112.414% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -340.371% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -248.555% |
| Absci Corporation | 234.48 Million USD | -811.047% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -29103.322% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -528.502% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -1194.038% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -305.878% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -669.275% |
| Allakos Inc. | 243.61 Million USD | -776.903% |
| Imunon, Inc. | 21.91 Million USD | -9646.401% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -728.977% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -243.711% |
| BioAtla, Inc. | 119.65 Million USD | -1685.274% |
| NLS Pharmaceutics AG | 1.84 Million USD | -115581.554% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -66242.329% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -232.312% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -2126.74% |
| XOMA Corporation | 234.3 Million USD | -811.743% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -865.59% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -1597.517% |
| aTyr Pharma, Inc. | 122.06 Million USD | -1650.041% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -1288.032% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -268.142% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -335.587% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -1833.776% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -13993.45% |
| Akari Therapeutics, Plc | 4.35 Million USD | -48952.193% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -12438.482% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -23.248% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -69168.246% |
| UroGen Pharma Ltd. | 178.31 Million USD | -1098.032% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -353.805% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -384309.814% |
| Orgenesis Inc. | 14.55 Million USD | -14579.927% |
| Entera Bio Ltd. | 11.76 Million USD | -18057.442% |
| GH Research PLC | 226.3 Million USD | -843.978% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -3805.772% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -1888.368% |
| Xencor, Inc. | 952.69 Million USD | -124.23% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -27344.577% |
| Replimune Group, Inc. | 487.72 Million USD | -338.0% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -26367.593% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -229.44% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -69168.246% |
| Portage Biotech Inc. | 7.77 Million USD | -27361.409% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -47771.992% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -671.353% |
| OncoCyte Corporation | 74.89 Million USD | -2752.405% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -104964.557% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -36816.447% |
| Purple Biotech Ltd. | 44.3 Million USD | -4721.956% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -6159.811% |
| scPharmaceuticals Inc. | 94.47 Million USD | -2161.056% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -11738.337% |
| HilleVax, Inc. | 344.43 Million USD | -520.213% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -67161.429% |
| Tharimmune, Inc. | 10.94 Million USD | -19415.314% |
| Genprex, Inc. | 10.67 Million USD | -19919.723% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -330.521% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -2119.406% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -87955.359% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -51184.438% |
| OKYO Pharma Limited | 1.54 Million USD | -138502.018% |
| Savara Inc. | 177.56 Million USD | -1103.072% |
| Curis, Inc. | 77.28 Million USD | -2664.192% |
| Daré Bioscience, Inc. | 21.28 Million USD | -9937.597% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -3240.521% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -26318.786% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -10927.944% |
| BeiGene, Ltd. | 5.8 Billion USD | 63.202% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -17454.631% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | -2.281% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -496.792% |
| Erasca, Inc. | 395.29 Million USD | -440.41% |
| bluebird bio, Inc. | 619.16 Million USD | -245.019% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -49311.073% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 68.776% |
| DBV Technologies S.A. | 182.98 Million USD | -1067.424% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -49311.073% |
| Moderna, Inc. | 18.42 Billion USD | 88.406% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -11626.536% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -18337.968% |
| Molecular Templates, Inc. | 35.38 Million USD | -5937.428% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -1445.021% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -170.781% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -603.272% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -1955.128% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -358.784% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -581.548% |
| MacroGenics, Inc. | 306.82 Million USD | -596.246% |
| RenovoRx, Inc. | 1.46 Million USD | -145617.804% |
| Adicet Bio, Inc. | 207.29 Million USD | -930.523% |
| Prime Medicine, Inc. | 193.85 Million USD | -1001.992% |
| Aditxt, Inc. | 44.57 Million USD | -4692.066% |
| Adagene Inc. | 115.72 Million USD | -1745.887% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -47859.864% |
| Quantum-Si incorporated | 298.25 Million USD | -616.252% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | -43.616% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -27610.325% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -508.124% |
| SciSparc Ltd. | 11.18 Million USD | -19004.123% |
| Vericel Corporation | 353.65 Million USD | -504.038% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -17391.946% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -3654.306% |
| Generation Bio Co. | 374.75 Million USD | -470.027% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -738.833% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -1247.205% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -525.789% |
| Invivyd, Inc. | 229.18 Million USD | -832.112% |
| Relay Therapeutics, Inc. | 843.98 Million USD | -153.113% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -17454.196% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -1071.239% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -10359.376% |
| 2seventy bio, Inc. | 565.42 Million USD | -277.808% |
| ADMA Biologics, Inc. | 329.18 Million USD | -548.949% |
| Clene Inc. | 52.34 Million USD | -3981.357% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -3537.095% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -1544.589% |
| GeoVax Labs, Inc. | 9.28 Million USD | -22911.662% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -226.79% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -1961.769% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -1538.384% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -2089.829% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -2908.892% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -780.724% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | -8.986% |
| Evaxion Biotech A/S | 12.88 Million USD | -16474.491% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -747.506% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -183.813% |
| Trevena, Inc. | 40.6 Million USD | -5160.985% |
| Surrozen, Inc. | 46.08 Million USD | -4535.901% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -845.83% |
| Cingulate Inc. | 3.49 Million USD | -61084.653% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -12746.371% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -3151.976% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -18182.338% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -695.563% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -185.227% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -1596.87% |
| Clearmind Medicine Inc. | 4.32 Million USD | -49299.418% |
| Kronos Bio, Inc. | 213.27 Million USD | -901.61% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -1236.944% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -24854.098% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -479.723% |
| Statera Biopharma, Inc. | 21.16 Million USD | -9990.953% |
| ImmunityBio, Inc. | 504.45 Million USD | -323.474% |
| Korro Bio, Inc. | 221.66 Million USD | -863.726% |
| Kineta, Inc. | 10.28 Million USD | -20678.358% |
| BioVie Inc. | 25.2 Million USD | -8374.269% |
| Codexis, Inc. | 136.56 Million USD | -1464.299% |
| Celularity Inc. | 143.88 Million USD | -1384.633% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -236.226% |
| Celcuity Inc. | 191.21 Million USD | -1017.158% |
| Virax Biolabs Group Limited | 5.48 Million USD | -38853.958% |
| Cibus, Inc. | 544.41 Million USD | -292.392% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -1596.843% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -10298.282% |
| IN8bio, Inc. | 33.7 Million USD | -6237.248% |
| Kodiak Sciences Inc. | 479.37 Million USD | -345.629% |
| Annexon, Inc. | 297.67 Million USD | -617.638% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -1134.74% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -1453.967% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -10075.882% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 28.556% |
| Eyenovia, Inc. | 28.77 Million USD | -7322.757% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -826.665% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -29471.193% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -3406.258% |
| Arcellx, Inc. | 825.13 Million USD | -158.895% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -2516.734% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -362.111% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -6847.067% |
| Moolec Science SA | 24.05 Million USD | -8781.948% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -588.826% |
| Geron Corporation | 394.07 Million USD | -442.084% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -2000.308% |
| Royalty Pharma plc | 16.38 Billion USD | 86.96% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -259.048% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -30440.093% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -17661.427% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -844.981% |
| Humacyte, Inc. | 128.22 Million USD | -1566.022% |
| Structure Therapeutics Inc. | 482.01 Million USD | -343.184% |
| 89bio, Inc. | 596.26 Million USD | -258.265% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -747.197% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -115371.514% |
| Genelux Corporation | 27.89 Million USD | -7558.635% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -2289.431% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -831.104% |
| Notable Labs, Ltd. | 19.54 Million USD | -10832.005% |
| Liquidia Corporation | 120.43 Million USD | -1673.815% |
| Mustang Bio, Inc. | 17.74 Million USD | -11940.486% |
| Immunovant, Inc. | 666.71 Million USD | -220.412% |
| Quantum-Si incorporated | 298.25 Million USD | -616.252% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -1379.369% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -3844.282% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -1116.902% |
| Acasti Pharma Inc. | 73.3 Million USD | -2814.356% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -46826.431% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -8079.479% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | -121.417% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -41061.016% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -9277.213% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -4039.726% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -1082.252% |
| PepGen Inc. | 143.05 Million USD | -1393.319% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -5489.719% |
| United Therapeutics Corporation | 7.16 Billion USD | 70.194% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -11034.861% |
| Solid Biosciences Inc. | 164.93 Million USD | -1195.159% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -36278.203% |
| Immuneering Corporation | 102.58 Million USD | -1982.403% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -49480.214% |
| Silo Pharma, Inc. | 7.74 Million USD | -27477.9% |
| Belite Bio, Inc | 94.64 Million USD | -2157.162% |
| XOMA Corporation | 234.3 Million USD | -811.743% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -816.095% |
| Bionomics Limited | 27.64 Million USD | -7626.196% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -432.188% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -1889.257% |
| uniQure N.V. | 831.68 Million USD | -156.854% |
| Cassava Sciences, Inc. | 151.66 Million USD | -1308.533% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -47859.864% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -679.971% |
| Forte Biosciences, Inc. | 38.98 Million USD | -5380.305% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -52346.924% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -5700.068% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -29471.193% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -60709.081% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -17971.424% |
| Altimmune, Inc. | 210.64 Million USD | -914.158% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -174.621% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -1889.257% |
| Compugen Ltd. | 121.33 Million USD | -1660.614% |
| Peak Bio, Inc. | 2.59 Million USD | -82175.869% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -1139.633% |
| Benitec Biopharma Inc. | 52.21 Million USD | -3991.597% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -524.884% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -6043.338% |
| Zura Bio Limited | 100.84 Million USD | -2018.365% |
| PolyPid Ltd. | 15.37 Million USD | -13796.845% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -1690.841% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -6043.338% |
| Instil Bio, Inc. | 325.63 Million USD | -556.028% |
| argenx SE | 4.54 Billion USD | 52.972% |
| Immunome, Inc. | 148.54 Million USD | -1338.147% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -1261.736% |
| Verona Pharma plc | 308.12 Million USD | -593.3% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -2356.586% |
| Shattuck Labs, Inc. | 159.56 Million USD | -1238.788% |
| CervoMed Inc. | 9.97 Million USD | -21321.093% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -1033.539% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -18658.544% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -1090.727% |
| Moolec Science SA | 24.05 Million USD | -8781.948% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -34819.983% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -1135.208% |
| AnaptysBio, Inc. | 452.38 Million USD | -372.209% |
| Design Therapeutics, Inc. | 289.64 Million USD | -637.537% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -2833.365% |
| NeurAxis, Inc. | 509.49 Thousand USD | -419179.958% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -39328.258% |
| Lumos Pharma, Inc. | 40.63 Million USD | -5156.713% |
| Achilles Therapeutics plc | 161.45 Million USD | -1223.099% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -2356.586% |
| 180 Life Sciences Corp. | 5.25 Million USD | -40516.651% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -2933.21% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -24854.098% |
| Nutriband Inc. | 7.51 Million USD | -28317.976% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -738.767% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -971.858% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -2703.001% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -3588.485% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -305.709% |
| Palisade Bio, Inc. | 14.05 Million USD | -15102.27% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -915.822% |
| Beam Therapeutics Inc. | 1.45 Billion USD | -46.345% |
| Neurogene Inc. | 222.57 Million USD | -859.785% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -230.367% |
| AEON Biopharma, Inc. | 6.84 Million USD | -31108.517% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -371.535% |
| Sesen Bio, Inc. | 189.17 Million USD | -1029.237% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -685.76% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -15479.37% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -173.752% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -700.102% |
| Athira Pharma, Inc. | 160.24 Million USD | -1233.098% |
| Vaccinex, Inc. | 3.63 Million USD | -58732.911% |
| HCW Biologics Inc. | 28.51 Million USD | -7391.928% |
| XOMA Corporation | 234.3 Million USD | -811.743% |
| Nektar Therapeutics | 398.03 Million USD | -436.695% |
| Arvinas, Inc. | 1.3 Billion USD | -63.745% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -12438.482% |
| Merus N.V. | 458.49 Million USD | -365.922% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -945.293% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -1085.447% |
| Rezolute, Inc. | 132.73 Million USD | -1509.365% |
| Clene Inc. | 52.34 Million USD | -3981.357% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -14214.128% |
| BeyondSpring Inc. | 24.8 Million USD | -8511.025% |
| Synlogic, Inc. | 75.55 Million USD | -2727.562% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -17908.961% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -22713.146% |
| Peak Bio, Inc. | 2.59 Million USD | -82175.869% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -1121.865% |
| Krystal Biotech, Inc. | 818.35 Million USD | -161.039% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -788.471% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -194.332% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -59618.174% |
| MannKind Corporation | 475.19 Million USD | -349.544% |
| Ikena Oncology, Inc. | 192.09 Million USD | -1012.083% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -15872.955% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -1733.054% |
| Gossamer Bio, Inc. | 311.91 Million USD | -584.871% |
| CohBar, Inc. | 16.36 Million USD | -12953.076% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -5975.201% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -29103.322% |
| Legend Biotech Corporation | 1.84 Billion USD | -15.558% |
| Mural Oncology plc | 301.74 Million USD | -607.956% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -6743.578% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -37506.878% |
| Disc Medicine, Inc. | 367.99 Million USD | -480.502% |
| Champions Oncology, Inc. | 26.13 Million USD | -8074.74% |
| REGENXBIO Inc. | 573.97 Million USD | -272.184% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -78783.159% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -1283.69% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -17590.438% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -528.236% |
| Vaxart, Inc. | 91.83 Million USD | -2226.28% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -3466.084% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -1340.213% |
| Cellectis S.A. | 334.27 Million USD | -539.071% |
| Longeveron Inc. | 12.17 Million USD | -17441.657% |
| Repare Therapeutics Inc. | 253.9 Million USD | -741.361% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 34.564% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -963.607% |
| Revolution Medicines, Inc. | 2.08 Billion USD | -2.281% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -131359.877% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -669.225% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -1209.779% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -1439.687% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -8270.124% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 90.602% |
| Denali Therapeutics Inc. | 1.15 Billion USD | -85.128% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -17391.946% |
| Veru Inc. | 50.59 Million USD | -4122.125% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -4589.533% |
| Cingulate Inc. | 3.49 Million USD | -61084.653% |
| Passage Bio, Inc. | 150.54 Million USD | -1318.993% |
| Context Therapeutics Inc. | 16.06 Million USD | -13199.248% |
| Exicure, Inc. | 11.58 Million USD | -18347.522% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -468.072% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -1221.577% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -12126.551% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -542.0% |
| Nuvalent, Inc. | 732.38 Million USD | -191.681% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -14194.779% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -2285.402% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -14953.365% |
| OmniAb, Inc. | 401.98 Million USD | -431.419% |
| Anew Medical, Inc. | 19.45 Million USD | -10879.791% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -7892.886% |
| Lipocine Inc. | 23 Million USD | -9187.493% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -1427.98% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -599.106% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -2444.902% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -1657.63% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -26821.525% |
| Sage Therapeutics, Inc. | 882.27 Million USD | -142.126% |
| Ocugen, Inc. | 64.54 Million USD | -3209.562% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -1615.277% |
| Q32 Bio Inc. | 306.11 Million USD | -597.841% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -50665.756% |
| Alumis Inc. Common Stock | 89.61 Million USD | -2283.858% |
| Equillium, Inc. | 50.53 Million USD | -4127.633% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -2740.911% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -5075.771% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -125497.156% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -8071.925% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -3215.006% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -57215.756% |
| Dominari Holdings Inc. | 57.55 Million USD | -3611.427% |
| Edesa Biotech, Inc. | 8.89 Million USD | -23928.324% |
| vTv Therapeutics Inc. | 11.01 Million USD | -19288.482% |
| Bio-Techne Corporation | 2.81 Billion USD | 24.064% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -127.957% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -163.261% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -669.353% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -5022.591% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -219.991% |
| Nkarta, Inc. | 378.88 Million USD | -463.818% |
| BioCardia, Inc. | 2.98 Million USD | -71417.342% |
| Iterum Therapeutics plc | 26.25 Million USD | -8035.203% |